Currently, there is limited availability of diagnostic tests for G6PD deficiency, appropriate for widespread use in malaria endemic regions. This creates a challenge to ensuring safe, radical cure treatment for malaria patients. The purpose of this call is to solicit information from companies that are working on G6PD diagnostic solutions, with the potential to address testing needs in low- and middle-income countries (LMICs), particularly in non-laboratory settings. Select companies with available prototypes will be considered for participation in future laboratory and operational evaluations, including field studies in LMICs, to further support product development.
Publication date: February 2020